Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up.

ABSTRACT:

Background

Pneumonia with severe respiratory failure represents the principal cause of death in COVID-19, where hyper-inflammation plays an important role in lung damage. An effective treatment aiming at reducing the inflammation without preventing virus clearance is thus urgently needed. Tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, has been proposed for treatment of patients with COVID-19.

Methods

A retrospective cohort study at the Montichiari Hospital, Brescia, Italy, was conducted. We included consecutive patients with COVID-19 related pneumonia at the early stage of respiratory failure, all treated with a standard protocol (hydroxychloroquine 400 mg daily, lopinavir 800 mg plus ritonavir 200 mg per day). We compared survival rate and clinical status i

SUBMITTER: De Rossi N 

PROVIDER: S-EPMC7366117 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature